Recently, Liu et al. published a large study with 144 metastatic melanoma patients treated with anti-PD-1 (85 pembrolizumab,- and 59 nivolumab-treated), either as a first (n = 71),- or a second-line therapy (n = 73) [58]. Here, PDCD1 is linked to metastatic melanoma.